Bright Minds Biosciences Inc.
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Bright Minds Biosciences Inc. is a biotechnology firm dedicated to creating innovative treatments for patients facing severe and debilitating neurological and neuropsychiatric conditions. The company's pipeline emphasizes highly selective serotonergic agonists, precisely engineered to target 5-HT2C, 5-HT2A, and combined 5-HT2C/A receptors. Its lead compound, BMB-101, has advanced to Phase 2 clinical trials for developmental and epileptic encephalopathies and absence epilepsy, and is also being evaluated for Prader-Willi Syndrome. Additionally, BMB-201 is in preclinical development for pain and depression, having demonstrated efficacy comparable to morphine in early models, while BMB-202 is undergoing preclinical assessment for rapid-onset depression. The company engages in strategic collaborations with entities such as the National Institutes of Health for epilepsy and pain management programs, and the University of Texas Medical Branch for impulse control disorders including binge eating. Founded in 2019, Bright Minds Biosciences is headquartered in New York, NY.
Company News
Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
Bright Minds Biosciences to Present at Upcoming Conferences
What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now?
Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet
Vistagen Appoints Douglas J. Williamson to its Board of Directors
Wall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?
All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Recommendation of “Moderate Buy” from Brokerages
Bright Minds Biosciences to Present at Upcoming Conferences
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock
Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating
Bright Minds Biosciences Announces Launch of US$100 Million Public Offering
New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday
Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)
Bright Mind Biosciences shares surge on positive epilepsy drug trial results